RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Ronckers, Cecile M.; Tytgat, Lieve; van den Heuvel-Eibrink, Marry M.; Teepen, Jop; Kremer, Leontine C M; Clement, Sarah; van Santen, Hanneke M.

doi:https://doi.org/10.1016/j.ejca.2017.02.019

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

DSpace/Manakin Repository

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Ronckers, Cecile M.; Tytgat, Lieve; van den Heuvel-Eibrink, Marry M.; Teepen, Jop; Kremer, Leontine C M; Clement, Sarah; van Santen, Hanneke M.

(2017) European Journal of Cancer, volume 77, pp. 21 - 23

(Comment)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Oncology, Cancer Research, Letter

DOI: https://doi.org/10.1016/j.ejca.2017.02.019

ISSN: 0959-8049

Publisher: Elsevier Limited

Note: Funding Information: Dr. CM Ronckers is supported by Dutch Cancer Society grant # UVA 2012-5517.

(Peer reviewed)